Related references
Note: Only part of the references are listed.Use of vasoactive/vasodilating drugs for systemic sclerosis (SSc)-related digital ulcers (DUs) in expert tertiary centres: results from the analysis of the observational real-life DeSScipher study
Jelena Blagojevic et al.
CLINICAL RHEUMATOLOGY (2020)
Management of Raynaud's phenomenon in systemic sclerosis-a practical approach
Andreu Fernandez-Codina et al.
JOURNAL OF SCLERODERMA AND RELATED DISORDERS (2019)
Nifedipine cream versus sildenafil cream for patients with secondary Raynaud phenomenon: A randomized, double-blind, controlled pilot study
Ximena Wortsman et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Treatment Algorithms for Systemic Sclerosis According to Experts
Andreu Fernandez-Codina et al.
ARTHRITIS & RHEUMATOLOGY (2018)
A multi-centre, blinded, randomised, placebo-controlled, laboratory-based study of MQX-503, a novel topical gel formulation of nitroglycerine, in patients with Raynaud phenomenon
Laura K. Hummers et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial
Padmanabha D. Shenoy et al.
RHEUMATOLOGY (2010)
Clinical burden of digital vasculopathy in limited and diffuse cutaneous systemic sclerosis
S. I. Nihtyanova et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Share Paper
